With regard to Health Canada's decisions taken with respect to Mifegymiso: (a) what were the conditions imposed by Health Canada during the initial review and approval of the drug on the (i) manufacturer, (ii) distributor, (iii) retailers, (iv) prescribers, doctors and medical professionals, (v) consumers; and (b) for each of the conditions listed in (a), (i) what rationale was given by Health Canada, (ii) what studies did Health Canada cite to justify the conditions, (iii) which stakeholders were consulted by Health Canada?
In the House of Commons on March 19th, 2018. See this statement in context.